COVID, Volume 3, Issue 7 (July 2023) – 9 articles
The efficacy and safety of subunit and synthetic peptides vaccines in clinical trial phases and monoclonal antibodies with the ability to suppress the development of SARS-CoV-2, which entered into clinical trials until March 2023, were evaluated. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.